Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study

Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study

Policy decisions about prostate cancer screening require data on the natural history of histological cancers and the resulting impact of screening. However, the gold standard procedure required to identify true positive histological cancer is a full autopsy of the gland which is not possible in scre...

Full description

Bibliographic Details
Main Authors:	Leal, J, Welton, N, Martin, R, Donovan, J, Hamdy, F, Neal, D, Noble, S, Lane, A, Wolstenholme, J
Format:	Journal article
Language:	English
Published:	Elsevier 2018

Similar Items

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study
by: Hamdy, F, et al.
Published: (2006)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
by: Avery, K, et al.
Published: (2007)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
by: Collin, S, et al.
Published: (2009)

The protect (prostate testing for cancer and treatment) study: Advanced cases found through a UK screening study
by: Neal, D, et al.
Published: (2006)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
by: Avery, K, et al.
Published: (2008)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
by: Oliver, SE, et al.
Published: (2004)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
by: Young, GJ, et al.
Published: (2017)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
by: Hamdy, F, et al.
Published: (2006)

Measurement of the insulin-like growth factor (IGF)-axis does not enhance the specificity of PSA-based prostate cancer screening.
by: Oliver, SE, et al.
Published: (2002)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
by: Zuccolo, L, et al.
Published: (2013)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Screening for prostate cancer. The case against.
by: Donovan, J, et al.
Published: (2005)

Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies
by: Leal, J, et al.
Published: (2014)

Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies.
by: Leal, J, et al.
Published: (2014)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
by: Dimitropoulou, P, et al.
Published: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
by: Dimitropoulou, P, et al.
Published: (2011)

Prostate cancer: screening approaches
by: Donovan, J, et al.
Published: (2005)

Prostate cancer: screening approaches.
by: Donovan, J, et al.
Published: (2005)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
by: Brindle, L, et al.
Published: (2006)

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
by: Joanna C. Thorn, et al.
Published: (2023-06-01)

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
by: Harrison, S, et al.
Published: (2016)

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study
by: Mantica G, et al.
Published: (2022-10-01)

Screening for prostate cancer remains controversial.
by: Neal, D, et al.
Published: (2009)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
by: Avery, K, et al.
Published: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
by: Avery, K, et al.
Published: (2012)

Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial
by: Martin, RM, et al.
Published: (2018)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
by: Down, L, et al.
Published: (2011)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
by: Down, L, et al.
Published: (2011)

Prostate Cancer Screening with PSA: Ten Years’ Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania
by: Ausvydas Patasius, et al.
Published: (2020-11-01)

Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.
by: Burton, A, et al.
Published: (2012)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
by: Catto, J, et al.
Published: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
by: Catto, J, et al.
Published: (2011)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
by: Murad, A, et al.
Published: (2011)